pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
== Awards and fellowships == 1984 ACS Analytical Division's Chemical Instrumentation Award; 1985 Thomson Medal for International Service to Mass Spectrometry; 1990 and 1995 NSF Special Creativity Award; 1991 Frank H. Field & Joe Franklin Award, (ACS Award for Mass Spectrometry); 1997 Fisher Award (ACS Award for Analytical Chemistry); 2006 Distinguished Contribution in Mass Spectrometry Award; 2008 Robert Boyle Prize for Analytical Science; 2012 F.A. Cotton Medal for Excellence in Chemical Research of the American Chemical Society; 2013 Dreyfus Prize in the Chemical Sciences; 2014 ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, shared with graduate student Livia S. Eberlin; 2015 Member, National Academy of Sciences; 2017 Aston Medal, British Mass Spectrometry Society.
Because dextromethorphan (DXM) acts predominantly as the parent compound rather than through dextrorphan in Auvelity, the contribution of the active metabolite can largely be disregarded when analyzing Auvelity's pharmacological effects. Dextrorphan primarily provides NMDA channel blockade. However, DXM itself exhibits its strongest activity as a serotonin transporter (SERT) inhibitor and σ1 receptor agonist, while its NMDA antagonism is actually quite weak. In Auvelity, the conversion of DXM to dextrorphan by the CYP2D6 enzyme is substantially inhibited by bupropion, resulting in extremely high plasma concentrations of the parent DXM. Consequently, Auvelity's NMDA receptor antagonism is clinically quite limited, whereas σ1 receptor agonism and SERT inhibition become the dominant pharmacological actions. Based on pharmacokinetic data, it can be inferred that DXM in Auvelity may achieve approximately 60–85% whole-brain SERT occupancy, a level comparable to that of most SSRIs (selective serotonin reuptake inhibitors). In addition, σ1 receptor agonism, which was previously investigated as a target for antidepressant development, likely contributes to Auvelity's therapeutic efficacy. Bupropion produces relatively strong inhibition of the norepinephrine transporter (NET) and achieves approximately 14–28% dopamine transporter (DAT) occupancy, making it an NDRI (norepinephrine-dopamine reuptake inhibitor). Bupropion also antagonizes nicotinic acetylcholine receptors, acts as a weak positive allosteric modulator of the σ1 receptor, and inhibits 5-HT3 receptors.
18 October – A study indicates there has been a substantial increase of sentiment negativity and decrease of emotional neutrality in headlines across written popular news media since 2000. 19 October – A novel type of effective hydrogen storage using readily available salts is reported. 20 October A study of PNMN, the world's largest no-fishing zone, finds a "spillover benefit" for migratory species like bigeye and yellowfin tuna. The first data transmission to exceed 1 petabit per second (Pbit/s) using only a single laser and a single optical chip is demonstrated by European researchers. 21 October – News outlets report about a novel agricultural robot for viable weed control using lasers or "laserweeding". There are similar precision agriculture machines that have been reported before, also e.g. applying low amounts of herbicides and fertilizers with precision while mapping plant locations, in some cases autonomously. Their benefits may include "healthier crops and soil, decreased herbicide use, and reduced chemical and labor costs". 24 October The NHS launches 'Our Future Health', one of the world's largest health and genetic data gathering projects, aimed at building a long-term repository of information for researchers. Five million UK adults are invited to participate. "Hybrid viral particles (HVPs)" are reported, combining IAV and RSV in vitro. 25 October – A comprehensive annually scheduled study finds climate change is "undermining every dimension of global health monitored" and reports dire conclusions from tracking of impact indicators.
Placing the plate under blacklight (366 nm light) makes fluorescent compounds glow TLC plates containing a small amount of fluorescent compound (usually manganese-activated zinc silicate) in the adsorbent layer allow for visualisation of some compounds under UV-C light (254 nm). The adsorbent layer will fluoresce light-green, while spots containing compounds that absorb UV-C light will not. Placing the plate in a container filled with iodine vapours temporarily stains the spots. They typically become a yellow or brown colour. The TLC plate can either be dipped in or sprayed with a stain and sometimes heated depending on the stain used. Many stains exist for a large range of chemical moieties but some examples include: Potassium permanganate (no heating, for oxidisable groups) Ninhydrin (heating, amines and amino-acids) Acidic vanillin (heating, general reagent) Phosphomolybdic acid (no heating, general reagent) In the case of lipids, the chromatogram may be transferred to a polyvinylidene fluoride membrane and then subjected to further analysis, for example, mass spectrometry. This technique is known as far-eastern blot.
Sources: en.wikipedia.org
Paper chromatography is an analytical method used to separate colored chemicals or substances. It can also be used for colorless chemicals that can be located by a stain or other visualisation method after separation. It is now primarily used as a teaching tool, having been replaced in the laboratory by other chromatography methods such as thin-layer chromatography (TLC). This analytic method has three components, a mobile phase, stationary phase and a support medium (the paper). The mobile phase is generally a non-polar organic solvent in which the sample is dissolved. The stationary phase consists of (polar) water molecules that were incorporated into the paper when it was manufactured. The mobile phase travels up the stationary phase by capillary action, carrying the sample with it. The difference between TLC and paper chromatography is that the stationary phase in TLC is a layer of adsorbent (usually silica gel, or aluminium oxide), and the stationary phase in paper chromatography is less absorbent paper. A paper chromatography variant, two-dimensional chromatography, involves using two solvents and rotating the paper 90° in between. This is useful for separating complex mixtures of compounds having similar polarity, for example, amino acids.
In remains of combatants found in the region, archaeologists used tooth enamel to assess the presence of a high maize-consuming diet. Conclusively, archaeologists interpreted the levels of maize consumption in the combatants demonstrated a method of preparation for battle. Maize, or chicha, could have been used as a way to fortify the identities of the combatants, ensuring the elite status that came with the role they were carrying out. Maize consumption could be used in other contexts to shape social or political environments by promoting elite identities within.
=== Insulin pricing === In January 2019, lawmakers from the United States House of Representatives sent letters to Eli Lilly and other insulin manufacturers asking for explanations for rapidly raising insulin prices. The annual cost of insulin for people with type 1 diabetes in the US almost doubled from $2,900 to $5,700 over the period from 2012 to 2016. Renewed attention was brought to Eli Lilly's pricing of insulin in November 2022, after a verified Twitter account impersonating Eli Lilly posted on Twitter that insulin would now be free. The following year, the company announced that it would be reducing the out-of-pocket price of insulin to $35 a month. The company also stated that it would lower the price of Humalog from $275 a month to $66 and that it would offer insulin glargine at a 78% discount compared to rival company Sanofi. Despite this, the reduced costs will not apply to Eli Lilly's newer brands of insulin, and the company's pricing is still significantly higher than it was several decades prior.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.